KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
14 hedge funds and large institutions have $1.73M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 10 closing their positions.
26% less funds holding
Funds holding: 19 → 14 (-5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
48% less capital invested
Capital invested by funds: $3.36M → $1.73M (-$1.63M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$171K |
| 2 |
Bank of New York Mellon
New York
|
+$135K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$105K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$80.8K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$55.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
-$358K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$149K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$36K |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$28K |
| 5 |
William Blair & Company
Chicago,
Illinois
|
-$25K |
KBIO Hedge Fund Activity: Q3 2015 in Review
14 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q3 2015, worth a combined $1.73M — down 48% from $3.36M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of KBIO and 5 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $171K. The largest seller was Opus Point Partners Management, exiting entirely with an estimated $358K sold.
- 14 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q3 2015, down from 19 in Q2 2015.
- Funds reported $1.73M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q3 2015, down 48% quarter-over-quarter.
- 5 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q3 2015 and 10 closed out, a net change of -5 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q3 2015 was Renaissance Technologies, an estimated $171K added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q3 2015 was Opus Point Partners Management, an estimated $358K sold.
Based on aggregated 13F filings for Q3 2015.